Global Hepatitis E Diagnostic Tests Market size and share is currently valued at USD 54.61 million in 2024 and is anticipated to generate an estimated revenue of USD 78.62 million by 2032, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 4.6% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2024 – 2032
Market Overview
Hepatitis E is a liver disease caused by the Hepatitis E Virus (HEV), primarily transmitted through the fecal-oral route, often due to contaminated water sources. The World Health Organization (WHO) estimates that approximately 20 million people are infected with HEV annually, leading to around 56,600 deaths. The increasing prevalence of HEV infections, particularly in regions with inadequate sanitation and healthcare infrastructure, is driving the demand for effective diagnostic solutions.
Market Segmentation
By Test Type:
-
ELISA HEV IgM Test Kits: These kits are commonly used for the detection of acute HEV infections.
-
ELISA HEV IgG Test Kits: Utilized for identifying past infections and assessing immunity.
-
RT-PCR Test Kits: Provide molecular detection of HEV RNA, offering high sensitivity and specificity.
By Sample Type:
-
Blood Samples: Predominantly used for serological and molecular testing.
-
Stool Samples: Employed in certain diagnostic tests to detect HEV antigens or RNA.
By End-User:
-
Hospitals: Serve as primary centers for diagnosing and treating HEV infections.
-
Diagnostic Laboratories: Specialized facilities conducting various diagnostic tests.
-
Point-of-Care Settings: Enable rapid testing, especially in remote or underserved areas.
Regional Analysis
-
Asia-Pacific: Dominates the market with the largest revenue share, accounting for 36.9% in 2024. Countries like India, China, and Bangladesh report high HEV prevalence, necessitating widespread diagnostic testing.
-
North America: Experiences steady growth due to increasing awareness, improved healthcare access, and an escalating focus on infectious disease management. The U.S. healthcare system is adopting advanced diagnostic technologies like ELISA and PCR tests.
-
Europe: Benefits from advanced healthcare infrastructure and widespread awareness. Countries like the UK and Germany are witnessing a rise in HEV cases, driving the demand for efficient diagnostic tests.
-
Latin America and Middle East & Africa: Emerging markets with growing infrastructure development and increasing demand for energy storage solutions.
Explore More:
https://www.polarismarketresearch.com/industry-analysis/hepatitis-e-diagnostic-tests-market
Key Companies
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd
- Siemens Healthineers
- Bio-Rad Laboratories
- Thermo Fisher Scientific
- DiaSorin S.p.A.
- Perkin Elmer Inc.
- QIAGEN N.V.
- bioMérieux SA
- Merck KGaA
- Ortho Clinical Diagnostics
Conclusion
The global hepatitis E diagnostic tests market is poised for significant growth, driven by the increasing prevalence of HEV infections, advancements in diagnostic technologies, and rising awareness. As the demand for accurate and timely diagnostic solutions intensifies, opportunities for innovation and investment in this sector are expanding.
More Trending Latest Reports By Polaris Market Research:
Healthcare Analytical Testing Services Market
